Oct 31, 2024 Press Release for Alnylam
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 31, 2024
− Achieved Third Quarter 2024 Global Net Product Revenues of
− Submitted Regulatory Applications in
− Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of
“Alnylam continued to deliver robust results commercially and clinically in the third quarter. We achieved 34% year-over-year growth, with global net product revenues of
Third Quarter 2024 and Recent Significant Business Highlights
Commercial Performance
Total TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)
-
Continued growth momentum in total TTR, achieving global net product revenues for ONPATTRO and AMVUTTRA for the third quarter of
$50 million and$259 million , respectively, which combined represent 34% TTR annual growth compared to Q3 2023.
Total Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)
-
Achieved global net product revenues for GIVLAARI and OXLUMO for the third quarter of
$71 million and$40 million , respectively, which combined represent 34% Rare annual growth compared to Q3 2023.
R&D Highlights
-
Presented detailed results from the positive HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) at the
European Society of Cardiology Congress (ESC).-
Additional data from HELIOS-B, including echocardiographic and biomarker data, were presented at the Heart Failure Society of America Annual
Scientific Meeting 2024 (HFSA). -
Based on these positive results,
Alnylam submitted a supplemental New Drug Application (sNDA) to theU.S. Food and Drug Administration (FDA) using a Priority Review Voucher, as well as a Type II Variation to theEuropean Medicines Agency (EMA), for vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy.
-
Additional data from HELIOS-B, including echocardiographic and biomarker data, were presented at the Heart Failure Society of America Annual
-
Today announced positive initial results from the multiple dose portion of the Phase 1 study of mivelsiran in patients with Alzheimer’s disease.
- Following a second 50 mg dose of mivelsiran at month 6, further reductions of sAPPβ were observed at month 7, with patients achieving greater than 90% lowering of sAPPβ.
- No new safety signals have been identified, and no significant abnormalities have been seen on CSF safety labs such as total protein and CSF white cell count, or on the exploratory biomarker neurofilament light chain.
-
Presented the design of the cAPPricorn-1 Phase 2 study of mivelsiran in patients with cerebral amyloid angiopathy (CAA) at the 2024
International CAA Conference . -
Initiated a Phase 1 study of ALN-HTT02 in adult patients with Huntington’s disease.
-
Exon1 targeting strategy and design of the Phase 1 study were presented at the European Huntington's Disease Network (EHDN) & Enroll-HD 2024
Congress . - Nonclinical data supporting the tolerability of deep and sustained HTT-lowering in wild-type nonhuman primates after single and repeated intrathecal administration of ALN-HTT02 were also shared.
-
Exon1 targeting strategy and design of the Phase 1 study were presented at the European Huntington's Disease Network (EHDN) & Enroll-HD 2024
- Today announced the decision to suspend further clinical development of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase for the treatment of type 2 diabetes mellitus. This decision reflects portfolio prioritization efforts to allocate clinical, managerial and financial resources carefully to bring transformative medicines to patients.
Additional Business Updates
-
Alnylam hosted a TTR Investor Day featuring presentations fromAlnylam senior leaders and an external expert related to the Company's TTR business. A replay of the webcast is available on the Company's website. -
Appointed
Robert Hesslein as Chief Legal Officer and Corporate Secretary. -
Named one of
Fast Company Top 100 Workplaces for Innovators in 2024. - Recognized by Science magazine as a Top Employer for the sixth consecutive year.
Upcoming Events
Financial Results for the Quarter Ended
|
Three Months Ended
|
|||||
(In thousands, except per share amounts) |
|
2024 |
|
|
2023 |
|
Net product revenues |
$ |
420,146 |
|
|
$ |
313,153 |
Net revenue from collaborations |
$ |
57,387 |
|
|
$ |
427,472 |
Royalty revenue |
$ |
23,386 |
|
|
$ |
9,905 |
|
|
|
|
|||
GAAP Operating (loss) income |
$ |
(76,905 |
) |
|
$ |
213,867 |
Non-GAAP Operating (loss) income |
$ |
(31,101 |
) |
|
$ |
277,804 |
|
|
|
|
|||
GAAP Net (loss) income |
$ |
(111,570 |
) |
|
$ |
147,753 |
Non-GAAP Net (loss) income |
$ |
(64,199 |
) |
|
$ |
228,534 |
|
|
|
|
|||
GAAP Net (loss) income per common share - basic |
$ |
(0.87 |
) |
|
$ |
1.18 |
Non-GAAP Net (loss) income per common share - basic |
$ |
(0.50 |
) |
|
$ |
1.83 |
|
|
|
|
|||
GAAP Net (loss) income per common share - diluted |
$ |
(0.87 |
) |
|
$ |
1.15 |
Non-GAAP Net (loss) income per common share - diluted |
$ |
(0.50 |
) |
|
$ |
1.74 |
|
|
|
|
|||
For an explanation of our use of non-GAAP financial measures refer to the “Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure, see the tables at the end of this press release. |
||||||
Net Product Revenues
|
Three Months Ended |
|
Year over Year % Growth |
||||||
(In thousands, except percentages) |
2024 |
|
2023 |
|
As Reported |
|
At CER* |
||
ONPATTRO net product revenues |
$ |
50,293 |
|
$ |
81,589 |
|
(38)% |
|
(38)% |
AMVUTTRA net product revenues |
|
258,590 |
|
|
148,680 |
|
74% |
|
75% |
Total TTR net product revenues |
|
308,883 |
|
|
230,269 |
|
34% |
|
35% |
|
|
|
|
|
|
|
|
||
GIVLAARI net product revenues |
|
71,043 |
|
|
54,148 |
|
31% |
|
31% |
OXLUMO net product revenues |
|
40,220 |
|
|
28,736 |
|
40% |
|
40% |
Total Rare net product revenues |
|
111,263 |
|
|
82,884 |
|
34% |
|
34% |
|
|
|
|
|
|
|
|
||
Total net product revenues |
$ |
420,146 |
|
$ |
313,153 |
|
34% |
|
35% |
|
|
|
|
|
|
|
|
||
* CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the third quarter 2023. CER is a non-GAAP measure. |
|||||||||
-
Total net product revenues increased 34% and 35% at actual currency and CER, respectively, during the three months ended
September 30, 2024 , as compared to the same period in 2023, due to an increased number of patients receiving AMVUTTRA, GIVLAARI, and OXLUMO, partially offset by a decrease in patients receiving ONPATTRO primarily driven by switching to AMVUTTRA.
Net Revenues from Collaborations
-
Net revenues from collaborations decreased during the three months ended
September 30, 2024 , as compared to the same period in 2023, due to less revenue recognized under our collaborations with Roche and Regeneron. During 2023, we recognized$310 million of revenue from the upfront payment we received from Roche and a$65 million cumulative adjustment from the$100 million milestone we received in connection with our Regeneron Collaboration for achieving certain criteria during early clinical development for mivelsiran (formerly ALN-APP).
Operating Expenses
|
Three Months Ended
|
||||||
(In thousands, except percentages) |
|
2024 |
|
|
|
2023 |
|
Cost of goods sold |
$ |
81,980 |
|
|
$ |
79,473 |
|
Cost of goods sold as a percentage of net product revenues |
|
19.5 |
% |
|
|
25.4 |
% |
|
|
|
|
||||
Cost of collaborations and royalties |
$ |
3,925 |
|
|
$ |
4,836 |
|
|
|
|
|
||||
GAAP research and development expenses |
$ |
270,926 |
|
|
$ |
253,179 |
|
Non-GAAP research and development expenses |
$ |
251,132 |
|
|
$ |
224,024 |
|
|
|
|
|
||||
GAAP selling, general and administrative expenses |
$ |
220,993 |
|
|
$ |
199,175 |
|
Non-GAAP selling, general and administrative expenses |
$ |
194,983 |
|
|
$ |
164,393 |
|
Cost of Goods Sold
-
Cost of goods sold as a percentage of net product revenues decreased during the three months ended
September 30, 2024 , as compared to the same period in 2023, primarily due to higher costs in 2023 associated with cancelled manufacturing commitments and the impairment of ONPATTRO inventory that had been manufactured for future demand associated with the use of patisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy for which we did not receive regulatory approval in theU.S. , offset by increased rate of royalties payable on net sales of AMVUTTRA.
Research & Development (R&D) Expenses
-
GAAP and non-GAAP R&D expenses increased during the three months ended
September 30, 2024 , as compared to the same period in 2023, primarily due to increased costs associated with our preclinical activities as we develop our clinical pipeline of RNAi therapeutics targeting multiple tissues, increased clinical trial expenses associated with increased Phase 2 activities for the zilebesiran KARDIA-3 clinical trial, and increased employee compensation expenses.
Selling, General & Administrative (SG&A) Expenses
-
GAAP and non-GAAP SG&A expenses increased during the three months ended
September 30, 2024 , as compared to the same period in 2023, primarily due to higher costs associated with marketing investments to promote our TTR therapies and prepare for the potential launch of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy, and employee compensation.
Other Financial Highlights
-
Cash, cash equivalents and marketable securities were
$2.78 billion as ofSeptember 30, 2024 , as compared to$2.44 billion as ofDecember 31, 2023 , with the increase primarily due to improved operating performance and increased net proceeds from the issuance of common stock in connection with stock option exercises.
A reconciliation of our GAAP to non-GAAP financial results for the quarter is included in the tables at the end of this press release.
2024 Financial Guidance
Full year 2024 financial guidance is reiterated and consists of the following:
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 |
|
|
Net Product Revenue Growth vs. 2023 at reported FX rates1 |
|
27% to 33% |
Net Product Revenue Growth vs. 2023 at CER* |
|
28% to 34% |
Net revenues from collaborations and royalties |
|
|
GAAP R&D and SG&A expenses |
|
|
Non-GAAP R&D and SG&A expenses2 |
|
|
|
|
|
1 Uses |
||
2 Primarily excludes |
||
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended |
||
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and non-recurring gains outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company’s ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet.
Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into
The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release.
Conference Call Information
Management will provide an update on the Company and discuss third quarter 2024 results as well as expectations for the future via conference call on
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that is approved in
About AMVUTTRA® (vutrisiran)
AMVUTTRA (vutrisiran) is an RNAi therapeutic approved in
About GIVLAARI® (givosiran)
GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in
About OXLUMO® (lumasiran)
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the
About LNP Technology
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About
Alnylam Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam’s expectations regarding the potential launch of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy in the
This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. Vutrisiran has not been approved by any regulatory agency for the treatment of ATTR amyloidosis with cardiomyopathy. No conclusions can or should be drawn regarding its safety or effectiveness in treating cardiomyopathy in this population. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.
|
|||||||
|
|
|
|
||||
ASSETS |
(Unaudited) |
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,099,920 |
|
|
$ |
812,688 |
|
Marketable debt securities |
|
1,671,993 |
|
|
|
1,615,516 |
|
Marketable equity securities |
|
8,322 |
|
|
|
11,178 |
|
Accounts receivable, net |
|
353,852 |
|
|
|
327,787 |
|
Inventory |
|
75,987 |
|
|
|
89,146 |
|
Prepaid expenses and other current assets |
|
145,350 |
|
|
|
126,382 |
|
Total current assets |
|
3,355,424 |
|
|
|
2,982,697 |
|
Property, plant and equipment, net |
|
506,997 |
|
|
|
526,057 |
|
Operating lease right-of-use assets |
|
196,408 |
|
|
|
199,732 |
|
Restricted investments |
|
68,592 |
|
|
|
49,391 |
|
Other assets |
|
77,618 |
|
|
|
72,003 |
|
Total assets |
$ |
4,205,039 |
|
|
$ |
3,829,880 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
70,805 |
|
|
$ |
55,519 |
|
Accrued expenses |
|
946,168 |
|
|
|
713,013 |
|
Operating lease liability |
|
42,144 |
|
|
|
41,510 |
|
Deferred revenue |
|
71,030 |
|
|
|
102,753 |
|
Liability related to the sale of future royalties |
|
90,516 |
|
|
|
54,991 |
|
Total current liabilities |
|
1,220,663 |
|
|
|
967,786 |
|
Operating lease liability, net of current portion |
|
236,030 |
|
|
|
243,101 |
|
Deferred revenue, net of current portion |
|
1,012 |
|
|
|
188,175 |
|
Convertible debt |
|
1,023,654 |
|
|
|
1,020,776 |
|
Liability related to the sale of future royalties, net of current portion |
|
1,333,849 |
|
|
|
1,322,248 |
|
Other liabilities |
|
357,477 |
|
|
|
308,438 |
|
Total liabilities |
|
4,172,685 |
|
|
|
4,050,524 |
|
Commitments and contingencies (Note 13) |
|
|
|
||||
Stockholders’ equity (deficit): |
|
|
|
||||
Preferred stock, |
|
— |
|
|
|
— |
|
Common stock, |
|
1,289 |
|
|
|
1,259 |
|
Additional paid-in capital |
|
7,259,876 |
|
|
|
6,811,063 |
|
Accumulated other comprehensive loss |
|
(24,826 |
) |
|
|
(23,375 |
) |
Accumulated deficit |
|
(7,203,985 |
) |
|
|
(7,009,591 |
) |
Total stockholders’ equity (deficit) |
|
32,354 |
|
|
|
(220,644 |
) |
Total liabilities and stockholders’ equity (deficit) |
$ |
4,205,039 |
|
|
$ |
3,829,880 |
|
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam’s Annual Report on Form 10-K which includes the audited financial statements for the year ended
|
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Statements of Operations |
|
|
|
|
|
|
|
||||||||
Revenues: |
|
|
|
|
|
|
|
||||||||
Net product revenues |
$ |
420,146 |
|
|
$ |
313,153 |
|
|
$ |
1,195,397 |
|
|
$ |
895,186 |
|
Net revenues from collaborations |
|
57,387 |
|
|
|
427,472 |
|
|
|
403,273 |
|
|
|
469,778 |
|
Royalty revenue |
|
23,386 |
|
|
|
9,905 |
|
|
|
56,407 |
|
|
|
23,610 |
|
Total revenues |
|
500,919 |
|
|
|
750,530 |
|
|
|
1,655,077 |
|
|
|
1,388,574 |
|
|
|
|
|
|
|
|
|
||||||||
Operating costs and expenses: |
|
|
|
|
|
|
|
||||||||
Cost of goods sold |
|
81,980 |
|
|
|
79,473 |
|
|
|
203,864 |
|
|
|
196,241 |
|
Cost of collaborations and royalties |
|
3,925 |
|
|
|
4,836 |
|
|
|
16,689 |
|
|
|
28,307 |
|
Research and development |
|
270,926 |
|
|
|
253,179 |
|
|
|
826,063 |
|
|
|
732,274 |
|
Selling, general and administrative |
|
220,993 |
|
|
|
199,175 |
|
|
|
680,187 |
|
|
|
597,523 |
|
Total operating costs and expenses |
|
577,824 |
|
|
|
536,663 |
|
|
|
1,726,803 |
|
|
|
1,554,345 |
|
(Loss) income from operations |
|
(76,905 |
) |
|
|
213,867 |
|
|
|
(71,726 |
) |
|
|
(165,771 |
) |
Other (expense) income: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
(34,376 |
) |
|
|
(30,893 |
) |
|
|
(102,887 |
) |
|
|
(89,883 |
) |
Interest income |
|
32,146 |
|
|
|
25,425 |
|
|
|
90,973 |
|
|
|
65,155 |
|
Other expense, net |
|
(29,528 |
) |
|
|
(57,658 |
) |
|
|
(99,777 |
) |
|
|
(105,331 |
) |
Total other expense, net |
|
(31,758 |
) |
|
|
(63,126 |
) |
|
|
(111,691 |
) |
|
|
(130,059 |
) |
(Loss) income before income taxes |
|
(108,663 |
) |
|
|
150,741 |
|
|
|
(183,417 |
) |
|
|
(295,830 |
) |
Provision for income taxes |
|
(2,907 |
) |
|
|
(2,988 |
) |
|
|
(10,977 |
) |
|
|
(6,542 |
) |
Net (loss) income |
$ |
(111,570 |
) |
|
$ |
147,753 |
|
|
$ |
(194,394 |
) |
|
$ |
(302,372 |
) |
|
|
|
|
|
|
|
|
||||||||
Net (loss) income per common share - basic |
$ |
(0.87 |
) |
|
$ |
1.18 |
|
|
$ |
(1.53 |
) |
|
$ |
(2.43 |
) |
Net (loss) income per common share - diluted |
$ |
(0.87 |
) |
|
$ |
1.15 |
|
|
$ |
(1.53 |
) |
|
$ |
(2.43 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted-average common shares - basic |
|
128,590 |
|
|
|
125,220 |
|
|
|
127,159 |
|
|
|
124,667 |
|
Weighted-average common shares - diluted |
|
128,590 |
|
|
|
131,337 |
|
|
|
127,159 |
|
|
|
124,667 |
|
|
|||||||
|
Three Months Ended |
||||||
|
|
|
|
||||
Reconciliation of GAAP to |
|
|
|
||||
|
$ |
270,926 |
|
|
$ |
253,179 |
|
Less: Stock-based compensation expenses |
|
(19,794 |
) |
|
|
(29,155 |
) |
|
$ |
251,132 |
|
|
$ |
224,024 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Selling, general and administrative: |
|
|
|
||||
GAAP Selling, general and administrative |
$ |
220,993 |
|
|
$ |
199,175 |
|
Less: Stock-based compensation expenses |
|
(26,010 |
) |
|
|
(34,782 |
) |
Non-GAAP Selling, general and administrative |
$ |
194,983 |
|
|
$ |
164,393 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Operating (loss) income: |
|||||||
GAAP Operating (loss) income |
$ |
(76,905 |
) |
|
$ |
213,867 |
|
Add: Stock-based compensation expenses |
|
45,804 |
|
|
|
63,937 |
|
Non-GAAP Operating (loss) income |
$ |
(31,101 |
) |
|
$ |
277,804 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Net (loss) income: |
|
|
|
||||
GAAP Net (loss) income |
$ |
(111,570 |
) |
|
$ |
147,753 |
|
Add: Stock-based compensation expenses |
|
45,804 |
|
|
|
63,937 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
1,567 |
|
|
|
16,844 |
|
Non-GAAP Net (loss) income |
$ |
(64,199 |
) |
|
$ |
228,534 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Net (loss) income per common share- basic: |
|||||||
GAAP Net (loss) income per common share - basic |
$ |
(0.87 |
) |
|
$ |
1.18 |
|
Add: Stock-based compensation expenses |
|
0.36 |
|
|
|
0.51 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
0.01 |
|
|
|
0.13 |
|
Non-GAAP Net (loss) income per common share - basic |
$ |
(0.50 |
) |
|
$ |
1.83 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Net (loss) income per common share- diluted: |
|||||||
GAAP Net (loss) income per common share - diluted |
$ |
(0.87 |
) |
|
$ |
1.15 |
|
Add: Stock-based compensation expenses |
|
0.36 |
|
|
|
0.49 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
0.01 |
|
|
|
0.13 |
|
Non-GAAP Net (loss) income per common share - diluted |
$ |
(0.50 |
) |
|
$ |
1.74 |
|
Please note that the figures presented above may not sum exactly due to rounding
|
||
|
|
|
|
Three Months Ended |
|
ONPATTRO net product revenue growth, as reported |
(38 |
)% |
Add: Impact of foreign currency translation |
— |
|
ONPATTRO net product revenue growth at constant currency |
(38 |
)% |
|
|
|
AMVUTTRA net product revenue growth, as reported |
74 |
% |
Add: Impact of foreign currency translation |
1 |
|
AMVUTTRA net product revenue growth at constant currency |
75 |
% |
|
|
|
Total TTR net product revenue growth, as reported |
34 |
% |
Add: Impact of foreign currency translation |
1 |
|
Total TTR net product revenue growth at constant currency |
35 |
% |
|
|
|
GIVLAARI net product revenue growth, as reported |
31 |
% |
Add: Impact of foreign currency translation |
— |
|
GIVLAARI net product revenue growth at constant currency |
31 |
% |
|
|
|
OXLUMO net product revenue growth, as reported |
40 |
% |
Add: Impact of foreign currency translation |
— |
|
OXLUMO net product revenue growth at constant currency |
40 |
% |
|
|
|
Total net product revenue growth, as reported |
34 |
% |
Add: Impact of foreign currency translation |
1 |
|
Total net product revenue growth at constant currency |
35 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031367620/en/
(Investors and Media)
617-682-4340
(Investors)
617-551-8276
Source:
For Media Inquiries, please contact:
Christine Lindenboom
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam